+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia

Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia

Haematologica 77(6): 494-501

Background: Anaemia is a frequent finding in patients with cancer and may be due to different causes, including blunted erythropoietin production. Materials and Methods: In a pilot study, we administered recombinant human erythropoietin (rHuE-PO) to twelve patients with solid tumours and secondary anaemia. rHuEPO was given subcutaneously 5 d per week at escalating doses (75 to 150 U/kg per day): the aim of treatment was a Hb level gtoreq 10 g/dl without blood transfusion. We evaluated endogenous EPO production through serum EPO levels and erythroid marrow activity by means of serum transferrin receptor (TfR). Results: Six out of 12 subjects had defective endogenous EPO production. All patients but two responded to treatment with steady increases in Hb levels above 10 g/dl, and the median dose of rHuE-PO required for correction of anaemia was 75 U/kg. Response was associated with an early increase in serum TrF. Six patients developed functional iron deficiency and required iron supplementation to obtain response. Treatment improved functional ability in 4/10 responders. Conclusions: Subcutaneous rHuEPO can stimulate erythroid marrow activity in cancer anaemia, even in patients with advanced disease, and marrow response can be adequately monitored by serum TfR. Functional iron deficiency as a cause of nonresponse to rHuEPO is frequent in these patients and may require parental iron administration. Although erythropoietin can improve the anaemia of cancer, the decision to treat should be individualised for each patient, looking more at the quality of life and costeffectiveness than at cosmetic increases in the haemoglobin level.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 008633933

Download citation: RISBibTeXText

PMID: 1289186

Related references

Anaemia of lung cancer is due to impaired erythroid marrow response to erythropoietin stimulation as well as relative inadequacy of erythropoietin production. British Journal Of Haematology. 97(2): 297-299, 1997

Bone marrow erythroid precursor Ca++ regulates the response to human recombinant erythropoietin (rHuEPO) in hemodialysis patients. International Journal of Artificial Organs 13(11): 747-750, 1990

Bone Marrow Erythroid Precursor Ca ++ Regulates the Response to Human Recombinant Erythropoietin (Rhuepo) in Hemodialysis Patients. The International Journal of Artificial Organs 13(11): 747-750, 1990

Serum erythropoietin level and marrow erythroid infiltration predict response to recombinant human erythropoietin in myelodysplastic syndromes. Haematologica 78(2): 118-122, 1993

Bone marrow erythroid precursor cytoplasmic bmep calcium regulates the response to human recombinant erythropoietin rhuepo in hemodialysis hd patients. Kidney International 37(1): 290, 1990

Long-term follow-up of myelodysplastic syndrome patients with moderate/severe anaemia receiving human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3: independent positive impact of erythroid response on survival. British Journal of Haematology 158(1): 99, 2012

Stimulation of erythroid engraftment by recombinant human erythropoietin in ABO-compatible, HLA-identical, allogeneic bone marrow transplant patients. Leukemia 6(3): 215-219, 1992

The responsiveness to recombinant human erythropoietin in hemodialysis patients A possible role of cytoplasmic bone marrow erythroid precursor BFU-E Ca2+ levels. Nephrology Dialysis Transplantation 13(6): A242, 1998

Prediction of response to treatment with recombinant human erythropoietin in anaemia associated with cancer. Medical Oncology 15(Suppl. 1): S38-S46, 1998

Recombinant human erythropoietin is effective in correcting erythropoietin-deficient anaemia after allogeneic bone marrow transplantation. British Journal of Haematology 80(4): 545-549, 1992

In vitro effects of high titers of recombinant human erythropoietin on the bone marrow erythroid progenitors in patients with aplastic anemia. Japanese Journal of Clinical Hematology 30(4): 437-442, 1989

Recombinant human erythropoietin for anaemia in Chinese cancer patients on chemotherapy. Clinical Oncology ) 7(4): 272, 1995

Anaemia and its response to treatment with recombinant human erythropoietin in chronic kidney disease patients. West African Journal of Medicine 28(5): 295-299, 2010

Erythropoietin response to anaemia is not altered by surgery or recombinant human erythropoietin therapy. British Journal Of Haematology. 87(4): 695-699, 1994

Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: effect on erythroid repopulation in autologous versus allogeneic transplants. Bone Marrow Transplantation 13(4): 403-410, 1994